Revolution Medicines, Inc. (RVMD) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Redwood City, CA, 미국. 현재 CEO는 Mark A. Goldsmith.
RVMD 을(를) 보유 IPO 날짜 2020-02-13, 616 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $29.13B.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel therapies targeting RAS-addicted cancers. The company's pipeline includes several investigational programs, such as RMC-4630, an SHP2 inhibitor currently in Phase 1/2 trials for solid tumors including gynecologic and colorectal cancers, as well as RMC-5845, RMC-5552, RMC-6291, and RMC-6236, which target various components of RAS signaling pathways. Revolution Medicines has established a collaboration with Sanofi for the research and development of SHP2 inhibitors. Founded in 2014 and based in Redwood City, California, the company is advancing precision medicine approaches to address cancers driven by RAS mutations.
